SHANGHAI – Gracell Biotechnologies Co. Ltd., of Suzhou and Shanghai, has received an $85 million endorsement from topflight venture investors active in China's biotech scene led by Singapore's Temasek with Lilly Asia Ventures, and joined by Kington Capital, King Star Capital and Chengdu Miaoji.
SHANGHAI – Gracell Biotechnologies Co. Ltd., of Suzhou and Shanghai, has received an $85 million endorsement from topflight venture investors active in China's biotech scene led by Singapore's Temasek with Lilly Asia Ventures, and joined by Kington Capital, King Star Capital and Chengdu Miaoji. This is the second round of financing for Gracell; the startup received $10 million from 6 Dimensions Capital in 2017.
SHANGHAI – Alphamab Oncology Co. Ltd. now has more than $100 million in its coffers to push its four top antibody candidates through the clinic in China, the U.S., Japan and Australia for the next two years. The series A financing came from venture investors Advantech Capital, PAG, China Venture Capital Fund, Orbimed, Heritage Provider Network and Janchor Partners.
SHANGHAI – Alphamab Oncology Co. Ltd. now has more than $100 million in its coffers to push its four top antibody candidates through the clinic in China, the U.S., Japan and Australia for the next two years. The series A financing came from venture investors Advantech Capital, PAG, China Venture Capital Fund, Orbimed, Heritage Provider Network and Janchor Partners.
SHANGHAI – The verdict is in. The regulatory reforms that China kicked off in 2015 have opened the floodgates to an unprecedented number of early phase clinical trials being conducted in China.
SHANGHAI – The verdict is in. The regulatory reforms that China kicked off in 2015 have opened the floodgates to an unprecedented number of early phase clinical trials being conducted in China.
SHANGHAI – Alphamab Oncology Co. Ltd., of Suzhou, China, has kicked off a phase I study in Australia for KN-046, a PD-L1/CTLA-4, a potentially first-in-class bispecific that combines two domain antibodies fused with IgG Fc.
SHANGHAI – Alphamab Oncology Co. Ltd., of Suzhou, China, has kicked off a phase I study in Australia for KN-046, a PD-L1/CTLA-4, a potentially first-in-class bispecific that combines two domain antibodies fused with IgG Fc.
SHANGHAI – Alphamab Oncology Co. Ltd., of Suzhou, China, has kicked off a phase I study in Australia for KN-046, a PD-L1/CTLA-4, a potentially first-in-class bispecific that combines two domain antibodies fused with IgG Fc.
SHANGHAI – China's biotechs are benefiting from an unprecedented blood transfusion. Experienced executives from global pharma companies, and increasingly even big banks, are taking the leap to startups, leaving stable jobs behind. The incentive? Pay packages with stock options that can be worth tens of millions of dollars.
